689 related articles for article (PubMed ID: 29443657)
1. IL-2 and Beyond in Cancer Immunotherapy.
Wrangle JM; Patterson A; Johnson CB; Neitzke DJ; Mehrotra S; Denlinger CE; Paulos CM; Li Z; Cole DJ; Rubinstein MP
J Interferon Cytokine Res; 2018 Feb; 38(2):45-68. PubMed ID: 29443657
[TBL] [Abstract][Full Text] [Related]
2. Fine-tuned long-acting interleukin-2 superkine potentiates durable immune responses in mice and non-human primate.
Merchant R; Galligan C; Munegowda MA; Pearce LB; Lloyd P; Smith P; Merchant F; To MD
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058325
[TBL] [Abstract][Full Text] [Related]
3. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
4. NK cells and ILCs in tumor immunotherapy.
Sivori S; Pende D; Quatrini L; Pietra G; Della Chiesa M; Vacca P; Tumino N; Moretta F; Mingari MC; Locatelli F; Moretta L
Mol Aspects Med; 2021 Aug; 80():100870. PubMed ID: 32800530
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2: Old and New Approaches to Enhance Immune-Therapeutic Efficacy.
Dhupkar P; Gordon N
Adv Exp Med Biol; 2017; 995():33-51. PubMed ID: 28321811
[TBL] [Abstract][Full Text] [Related]
6. The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.
Wang Y; Zhang H; He YW
Front Immunol; 2019; 10():1574. PubMed ID: 31379815
[TBL] [Abstract][Full Text] [Related]
7. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
9. Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration.
Andersen MH; Gehl J; Reker S; Pedersen LØ; Becker JC; Geertsen P; thor Straten P
Semin Cancer Biol; 2003 Dec; 13(6):449-59. PubMed ID: 15001164
[TBL] [Abstract][Full Text] [Related]
10. [Interleukin-2 and cancer treatment].
Taguchi T
Gan To Kagaku Ryoho; 1986 Jan; 13(1):1-10. PubMed ID: 3510586
[TBL] [Abstract][Full Text] [Related]
11. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
12. Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.
Skrombolas D; Frelinger JG
Expert Rev Clin Immunol; 2014 Feb; 10(2):207-17. PubMed ID: 24410537
[TBL] [Abstract][Full Text] [Related]
13. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
Front Immunol; 2018; 9():2905. PubMed ID: 30619269
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy.
Figueroa JA; Reidy A; Mirandola L; Trotter K; Suvorava N; Figueroa A; Konala V; Aulakh A; Littlefield L; Grizzi F; Rahman RL; Jenkins MR; Musgrove B; Radhi S; D'Cunha N; D'Cunha LN; Hermonat PL; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2015 Mar; 34(2):154-87. PubMed ID: 25901860
[TBL] [Abstract][Full Text] [Related]
15. Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7.
Kim JH; Lee KJ; Lee SW
BMB Rep; 2021 Jan; 54(1):21-30. PubMed ID: 33407991
[TBL] [Abstract][Full Text] [Related]
16. Interleukin 2-Based Fusion Proteins for the Treatment of Cancer.
MacDonald A; Wu TC; Hung CF
J Immunol Res; 2021; 2021():7855808. PubMed ID: 34790830
[TBL] [Abstract][Full Text] [Related]
17. Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.
Atzpodien J; Kirchner H
Klin Wochenschr; 1990 Jan; 68(1):1-11. PubMed ID: 2407894
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
Topalian SL; Solomon D; Avis FP; Chang AE; Freerksen DL; Linehan WM; Lotze MT; Robertson CN; Seipp CA; Simon P
J Clin Oncol; 1988 May; 6(5):839-53. PubMed ID: 3259261
[TBL] [Abstract][Full Text] [Related]
19. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
Front Immunol; 2020; 11():7. PubMed ID: 32117218
[TBL] [Abstract][Full Text] [Related]
20. An Uncoupling of Canonical Phenotypic Markers and Functional Potency of
Lieberman NAP; DeGolier K; Haberthur K; Chinn H; Moyes KW; Bouchlaka MN; Walker KL; Capitini CM; Crane CA
Front Immunol; 2018; 9():150. PubMed ID: 29456538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
